Over the past 12 months, 7 insiders at Rapport Therapeutics, Inc. filed 53 open-market SEC Form 4 transactions on RAPP: 4 purchases worth $1.6M and 49 sales worth $6.6M. Insiders have been net sellers over this period. The most recent filing was on Jul 14, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 14, 26 | Abraham CeesayChief Executive Officer, Director | SELL | 5.5K | $40.57 | $218K |
| Mar 30, 26 | Cheryl GaultChief Operating Officer | SELL | 7.2K | $28.55 | $201K |
| Mar 25, 26 | Krishnaswamy YeleswaramChief Development Officer | SELL | 10.1K | $29.99 | $303K |
| Mar 5, 26 | Cheryl GaultChief Operating Officer | SELL | 2.0K | $28.93 | $58K |
| Feb 18, 26 | Abraham CeesayChief Executive Officer | SELL | 3.6K | $29.80 | $103K |
| Feb 17, 26 | David BredtChief Scientific Officer | SELL | 5.4K | $29.59 | $156K |
| Jan 20, 26 | Abraham CeesayChief Executive Officer | SELL | 5.8K | $26.12 | $152K |
| Jan 15, 26 | David BredtChief Scientific Officer | SELL | 8.3K | $27.40 | $223K |
| Dec 31, 25 | David BredtChief Scientific Officer | SELL | 6.6K | $30.05 | $197K |
| Dec 31, 25 | Krishnaswamy YeleswaramChief Development Officer | SELL | 2.8K | $30.05 | $85K |
| Dec 17, 25 | Abraham CeesayChief Executive Officer | SELL | 2.8K | $31.04 | $84K |
| Dec 15, 25 | David BredtChief Scientific Officer | SELL | 7.7K | $30.68 | $231K |
| Nov 26, 25 | Cheryl GaultChief Operating Officer | SELL | 5.0K | $30.10 | $151K |
| Nov 17, 25 | David BredtChief Scientific Officer | SELL | 5.3K | $25.39 | $136K |
| Nov 17, 25 | Abraham CeesayChief Executive Officer | SELL | 3.1K | $25.44 | $78K |
| Oct 15, 25 | David BredtChief Scientific Officer | SELL | 7.4K | $26.16 | $191K |
| Oct 15, 25 | Abraham CeesayChief Executive Officer | SELL | 4.6K | $26.17 | $120K |
| Sep 17, 25 | Abraham CeesayChief Executive Officer | SELL | 39.4K | $27.04 | $1.0M |
| Sep 15, 25 | David BredtChief Scientific Officer | SELL | 5.1K | $24.66 | $122K |
| Sep 12, 25 | Reid M HuberDirector | BUY | 20.4K | $24.48 | $499K |
| Sep 12, 25 | Steven M PaulDirector | BUY | 28.3K | $24.97 | $693K |
| Sep 11, 25 | Wendy B. YoungDirector | BUY | 3.5K | $22.60 | $79K |
| Sep 8, 25 | Cheryl GaultChief Operating Officer | SELL | 5.0K | $38.33 | $192K |
| Aug 15, 25 | David BredtChief Scientific Officer | SELL | 8.3K | $15.79 | $124K |
| Jul 15, 25 | David BredtChief Scientific Officer | SELL | 8.5K | $14.00 | $119K |
| Jun 16, 25 | David BredtChief Scientific Officer | SELL | 8.5K | $11.00 | $94K |
| May 15, 25 | David BredtChief Scientific Officer | SELL | 8.5K | $9.56 | $81K |
| Apr 15, 25 | David BredtChief Scientific Officer | SELL | 8.5K | $9.57 | $81K |
| Mar 14, 25 | David BredtChief Scientific Officer | SELL | 8.5K | $10.85 | $92K |
| Mar 13, 25 | Troy A. IgnelziChief Financial Officer | BUY | 100 | $9.98 | $998 |
| Mar 12, 25 | Troy A. IgnelziChief Financial Officer | BUY | 9.9K | $10.10 | $100K |
| Mar 12, 25 | Wendy B. YoungDirector | BUY | 6.0K | $10.21 | $61K |
| Jul 1, 24 | James HealyDirector | BUY | 4.9K | $26.06 | $122K |
| Jun 10, 24 | James HealyDirector | BUY | 470.6K | $17.00 | $8.0M |
Over the past 12 months, insiders at Rapport Therapeutics, Inc. filed 4 open-market purchases worth $1.6M and 49 sales worth $6.6M on RAPP, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 14, 26.
The largest recent open-market RAPP insider purchase in our data was $8.0M by James Healy, Director, filed on Jun 10, 24.
7 different insiders at Rapport Therapeutics, Inc. filed open-market SEC Form 4 transactions on RAPP over the last 12 months.
InsiderTape plots every RAPP insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Rapport Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →